search
Back to results

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease (MILESTONE)

Primary Purpose

Multivessel Coronary Artery Disease, Acute Coronary Syndrome

Status
Not yet recruiting
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
PCI
CABG
Sponsored by
American Heart of Poland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multivessel Coronary Artery Disease focused on measuring Multivessel Coronary Artery Disease, Left Main Narrowing, Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting, Drug-Eluting Stent, Fractional Flow Reserve, Instant wave-free ratio, virtual Fractional Flow Reserve

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Acute Coronary Syndrome without ST elevation (NSTE-ACS): Unstable Angina (Braunwald's class IB,IC,IIB,IIC,IIIB,IIIC) or Non ST Elevation Myocardial Infarction (NSTEMI) requiring prompt revascularization (within 72 hours)
  • Two vessel disease with proximal LAD stenosis or three vessel disease
  • Unprotected Left Main Coronary Artery (ULMCA) de novo disease with or without concomitant single or multivessel coronary artery disease
  • Syntax Score =<33
  • Patient eligible both for CABG and PCI, confirmed by interventional cardiologist and surgeon offering similar extension of revascularisation
  • Signed informed consent

Exclusion Criteria:

  • age <21
  • ST Elevation Myocardial Infarction;
  • Stable angina;
  • Patients in Killip IV class;
  • Patients required immediate PCI procedure (e.g. electric instability);
  • Patients unable to tolerate, obtain or comply with dual antiplatelet therapy for at least 1 year
  • History of haemorrhagic stroke within a year before procedure
  • Ischemic stroke or TIA within past 6 weeks.
  • End Stage Chronic renal insufficiency requiring dialysis
  • Concomitant structural or valve disease requiring cardiac surgery
  • Prior PCI of left main trunk one year prior to randomization
  • Prior PCI of any other coronary artery lesion within 1 year prior to randomization
  • Prior CABG at any time prior to randomization
  • Need for any concomitant cardiac surgery other than CABG (e.g. valve surgery, aortic repair, etc.), or intent that if the patient will be randomized to surgery, any cardiac surgical procedure other than isolated CABG will be performed
  • Patients requiring additional surgery (cardiac or non cardiac) within 1 year
  • Pregnancy or intention to become pregnant (women of child bearing age must have a recent negative pregnancy test prior to randomization)
  • Non cardiac co-morbidities with life expectancy less than 3 years

Sites / Locations

  • American Heart of Poland, Malopolska Centre for Heart and Vascular Disease
  • American Heart of Poland, 2-nd Department of Cardiology
  • American Heart of Poland,3-rd Depatment of Invasive Cardiology, Angiology and Electrophysiology
  • American Heart of Poland 1-st Department of Cardiology and Angiology
  • Silesian Centre for Heart Disease, Department of Cardiosurgery and Transplantation
  • Clinical University Hospital
  • Upper Silesian Heart Center of Medical Univeristy of Silesia

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PCI with DES implantation

CABG

Arm Description

Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents

Coronary Artery Bypass Grafting.On-pump or Off-pump CABG

Outcomes

Primary Outcome Measures

MACCE - Major Adverse Cardiac and Cerebral Events
The primary endpoint is a composite of all cause death, revascularization procedure: PCI or CABG. The hypothesis test is designed to show non-inferiority of PCI to CABG for the primary endpoint

Secondary Outcome Measures

SAE - Serious Adverse Events
ischemia driven revascularization, left ventricular ejection fraction, major and minor bleeding incidence, new onset of atrial fibrillation, de novo heart failure, unscheduled re-hospitalization
Procedural and post procedural complication
Procedural and post procedural complication: length of hospital stay and frequency of prolonged hospitalization ; return to work; readmissions and cause of readmissions; angina and functional status; medications.
Overall costs of treatment strategies.
Hospital costs and long-term cost-effectiveness.
Occurence of stent thrombosis or graft occlusion
Stent trombosis will be defined in accordance with ARC definition.
Hemorrhagic complications.
Hemorrhagic complications will be clasified according to TIMI scale.
Frequency and impact of complete revascularization
Complete revascularization will be defined on an anatomic basis and by revascularization of all significant ischemic areas.
LVEF
Left Ventricle Ejection Fraction

Full Information

First Posted
March 8, 2011
Last Updated
April 29, 2020
Sponsor
American Heart of Poland
Collaborators
Andrzej Frycz Modrzewski Kraków University, Kraków, Poland, Upper Silesian Heart Center of Medical University of Silesia, Katowice, Poland, Silesian Centre for Heart Diseases, Clinical University Hospital, Białystok, Poland
search

1. Study Identification

Unique Protocol Identification Number
NCT01311323
Brief Title
Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease
Acronym
MILESTONE
Official Title
Multivessel and Left Main Coronary Artery Stenting in Comparison With Surgical Revascularization in Patients With Non ST Elevation Acute Coronary Syndrome. Prospective, Clinical Randomized Trial (The MILESTONE Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 2021 (Anticipated)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
June 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
American Heart of Poland
Collaborators
Andrzej Frycz Modrzewski Kraków University, Kraków, Poland, Upper Silesian Heart Center of Medical University of Silesia, Katowice, Poland, Silesian Centre for Heart Diseases, Clinical University Hospital, Białystok, Poland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
MILESTONE STUDY is dedicated to problems connected with patients with multivessel coronary artery disease and/or with left main narrowing who present symptoms of acute ischemia. For such kind of patients according to current ACC/AHA guidelines CABG (surgical revascularization) is recommended as a treatment method. In comparison with CABG, recent studies have shown that PCI (percutaneous coronary intervention) is associated with a lower rate of periprocedural adverse events and similar long term event-free survival in patients with left main disease. Our latest non randomized registry and randomized LEMANS study, comparing LMCA (left main coronary artery) stenting with CABG confirmed above findings. LEMANS ACS (acute coronary syndrome) retrospective registry of patients with UPLMCA (unprotected LMCA) disease and non ST elevation ACS showed lower 30 day and trend toward lower one year mortality after PCI when compared with CABG. It should be stressed, that acute ischemia substantially increase the risk of CABG. In fact, there are limited data on the outcome of ULMCA stenting or CABG in patients with acute coronary syndromes (ACS). Similarly, all randomized studies comparing PCI vs CABG in multivessel disease included mainly patients with stable angina, small cohort of patients with unstable angina and they excluded patients with non ST elevation Myocardial infarction. In the SYNTAX study -largest PCI vs CABG trial, randomized patients were patients with low perioperative risk (logistic EUROSCORE <5) and ACS patients routinely excluded. High perioperative risk patients were included only in PCI registry.
Detailed Description
Within last decade, aging of the population and coexistence of multiple comorbidities influenced a risk of patients presenting with acute coronary syndrome (ACS) 10,11. Furthermore, a steady decline in ST elevation ACS incidence and increase in non-ST elevation acute coronary syndrome (NSTE-ACS) has been observed 10,12,13, associated with poorer long term prognosis 14,15. This is related to the complexity of coronary artery disease in patients with NSTE-ACS, as nearly half of them have multivessel disease (MVD) 15. The optimal revascularization strategy in this group of patients remains unknown. Due to clinical presentation in most of cases early or delayed invasive strategy is preferred by both American and European guidelines 16,17, however the method of revascularization is not specified. Due to high surgical risk presentation, immediate stenting of the culprit lesion and delayed complete percutaneous revascularization is becoming a common practice. On the other hand, basing on the anatomical criteria coronary artery bypass grafting (CABG) should be the standard of care 18. Very few reports addressed so far the problem of optimal revascularization strategy in patients presenting with MVD and NSTE-ACS. A hypothesis of a positive outcome can be derived from some previous studies comparing PCI and CABG in which most of patients enrolled presented with NSTE-ACS 7-9,19, including our experience. Aim and hypothesis: Hence, the purpose of this study will be to compare contemporary coronary angioplasty with coronary artery bypass grafting in a prospective, clinical, multicenter, randomized trial. The hypothesis of this study is the non-inferiority of PCI compared to CABG in terms of the primary composite endpoint (death, myocardial infarction, stroke). Method: Patients with multivessel coronary artery disease, left main and acute coronary syndrome without ST segment elevation, qualified for early invasive treatment, with a Syntax Score below 33, and in whom the invasive cardiologist and cardiac surgeon will recognize both PCI and CABG as possible to achieve complete revascularization will be enrolled to the study. In the case of centers without the Cardiac Surgery Department, "Heart Team" consultations will take place via videoconference, and records of coronarography and echocardiography will be shared via the TeleDICOM system. The main exclusion criteria will be the qualification for conservative treatment, surgery other than CABG due to structural heart defect, ST segment elevation myocardial infarction, stable coronary artery disease, immediate need for PCI. After fulfilling the inclusion criteria and lack of exclusion criteria, the patient will be randomized in a 1: 1 ratio to either PCI or CABG. The PCI procedure will be performed after assessing the hemodynamic significance of all lesions with vFFR, FFR or iFR or using the latest generation drug eluting stents, and the implantation will be optimized based on intravascular imaging. CABG procedures will be performed based on the experience of the respective center, including the OPCAB technique, and the internal mammary artery will be used in each case. The primary endpoint of the study will be all cause death, myocardial infarction, and stroke in one-year follow-up. To prove the assumed hypothesis of the study, with the test power of 80% alpha error 5% and the percentage of lost to follow-up at the level of 5%, the study should include 500 patients in each group. Secondary endpoints will be ischemia driven revascularization, left ventricular ejection fraction, major and minor bleeding incidence, new onset of atrial fibrillation, de novo heart failure, unscheduled re-hospitalization, quality of life, and cost effectiveness. After the hospitalization, patients will be subjected to strict secondary prevention principles, including cardiac and cardiac surgery rehabilitation, and will undergo four specialistic follow-up visits with cardiac echo and stress tests at selected time points. Anticipated outcomes: In the case of positive results of the study, the efficacy and safety of PCI in the studied group of patients will be confirmed. This will contribute to the creation of a new guidelines in a given area, translating into faster and easier access to rapid invasive treatment. It will also facilitate the decision-making process in centers without cardiac surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multivessel Coronary Artery Disease, Acute Coronary Syndrome
Keywords
Multivessel Coronary Artery Disease, Left Main Narrowing, Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting, Drug-Eluting Stent, Fractional Flow Reserve, Instant wave-free ratio, virtual Fractional Flow Reserve

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PCI with DES implantation
Arm Type
Experimental
Arm Description
Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents
Arm Title
CABG
Arm Type
Active Comparator
Arm Description
Coronary Artery Bypass Grafting.On-pump or Off-pump CABG
Intervention Type
Procedure
Intervention Name(s)
PCI
Other Intervention Name(s)
•Percutaneous coronary intervention, •Multivessel coronary disease, •Left main narrowing
Intervention Description
Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging
Intervention Type
Procedure
Intervention Name(s)
CABG
Other Intervention Name(s)
Multivessel coronary artery disease, Coronary artery bypass graft, Left Main narrowing
Intervention Description
Coronary Artery Bypass Graft
Primary Outcome Measure Information:
Title
MACCE - Major Adverse Cardiac and Cerebral Events
Description
The primary endpoint is a composite of all cause death, revascularization procedure: PCI or CABG. The hypothesis test is designed to show non-inferiority of PCI to CABG for the primary endpoint
Time Frame
One year after revascularization procedure
Secondary Outcome Measure Information:
Title
SAE - Serious Adverse Events
Description
ischemia driven revascularization, left ventricular ejection fraction, major and minor bleeding incidence, new onset of atrial fibrillation, de novo heart failure, unscheduled re-hospitalization
Time Frame
peri-hospital period, one month and one year and two years after revascularization procedure
Title
Procedural and post procedural complication
Description
Procedural and post procedural complication: length of hospital stay and frequency of prolonged hospitalization ; return to work; readmissions and cause of readmissions; angina and functional status; medications.
Time Frame
peri-hospital period, one month and one year after revascularization procedure
Title
Overall costs of treatment strategies.
Description
Hospital costs and long-term cost-effectiveness.
Time Frame
one year ofter revascularization procedure
Title
Occurence of stent thrombosis or graft occlusion
Description
Stent trombosis will be defined in accordance with ARC definition.
Time Frame
peri-hospital period, one month and one year after revascularization procedure
Title
Hemorrhagic complications.
Description
Hemorrhagic complications will be clasified according to TIMI scale.
Time Frame
peri-hospital period, one month and one year after revascularization procedure
Title
Frequency and impact of complete revascularization
Description
Complete revascularization will be defined on an anatomic basis and by revascularization of all significant ischemic areas.
Time Frame
one year after revascularization procedure
Title
LVEF
Description
Left Ventricle Ejection Fraction
Time Frame
6 and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Acute Coronary Syndrome without ST elevation (NSTE-ACS): Unstable Angina (Braunwald's class IB,IC,IIB,IIC,IIIB,IIIC) or Non ST Elevation Myocardial Infarction (NSTEMI) requiring prompt revascularization (within 72 hours) Two vessel disease with proximal LAD stenosis or three vessel disease Unprotected Left Main Coronary Artery (ULMCA) de novo disease with or without concomitant single or multivessel coronary artery disease Syntax Score =<33 Patient eligible both for CABG and PCI, confirmed by interventional cardiologist and surgeon offering similar extension of revascularisation Signed informed consent Exclusion Criteria: age <21 ST Elevation Myocardial Infarction; Stable angina; Patients in Killip IV class; Patients required immediate PCI procedure (e.g. electric instability); Patients unable to tolerate, obtain or comply with dual antiplatelet therapy for at least 1 year History of haemorrhagic stroke within a year before procedure Ischemic stroke or TIA within past 6 weeks. End Stage Chronic renal insufficiency requiring dialysis Concomitant structural or valve disease requiring cardiac surgery Prior PCI of left main trunk one year prior to randomization Prior PCI of any other coronary artery lesion within 1 year prior to randomization Prior CABG at any time prior to randomization Need for any concomitant cardiac surgery other than CABG (e.g. valve surgery, aortic repair, etc.), or intent that if the patient will be randomized to surgery, any cardiac surgical procedure other than isolated CABG will be performed Patients requiring additional surgery (cardiac or non cardiac) within 1 year Pregnancy or intention to become pregnant (women of child bearing age must have a recent negative pregnancy test prior to randomization) Non cardiac co-morbidities with life expectancy less than 3 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Agata Krauze, PhD
Phone
+48885805002
Email
agata.krauze@ahop.pl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Piotr P Buszman, MD,PhD, Assoc. Prof
Organizational Affiliation
American Heart of Poland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andrzej Bochenek, Prof, MD,PhD
Organizational Affiliation
American Heart of Poland
Official's Role
Principal Investigator
Facility Information:
Facility Name
American Heart of Poland, Malopolska Centre for Heart and Vascular Disease
City
Chrzanow
State/Province
Malopolska
ZIP/Postal Code
32-500
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Iwona Banasiewicz-Szkrobka, MD, PhD
Phone
0048602457602
Email
wilenka@wp.pl
First Name & Middle Initial & Last Name & Degree
Iwona Banasiewicz-Szkrobka, MD, PhD
First Name & Middle Initial & Last Name & Degree
Aleksander Zurakowski, MD,PhD
Facility Name
American Heart of Poland, 2-nd Department of Cardiology
City
Bielsko-Biala
State/Province
Silesia
ZIP/Postal Code
43-316
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bogdan Gorycki, MD,PhD
Phone
(+48) (33) 829 08 63; (33) 810
First Name & Middle Initial & Last Name & Degree
Bogdan Gorycki, MD,PhD
Facility Name
American Heart of Poland,3-rd Depatment of Invasive Cardiology, Angiology and Electrophysiology
City
Dabrowa Gornicza
State/Province
Silesia
ZIP/Postal Code
41-300
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marek Kondys, MD,PhD
Phone
(+48) (33) 829 08 63; (33) 810
First Name & Middle Initial & Last Name & Degree
Marek Kondys, MD,PhD
First Name & Middle Initial & Last Name & Degree
Marcin Debinski, MD,PhD
Facility Name
American Heart of Poland 1-st Department of Cardiology and Angiology
City
Ustron
State/Province
Silesia
ZIP/Postal Code
43-450
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marek Krol, MD,PhD
Phone
(+48) (33) 854 58 57, (33) 854
Email
m.krol@klinikiserca.pl
First Name & Middle Initial & Last Name & Degree
Marek Krol, MD,PhD
Facility Name
Silesian Centre for Heart Disease, Department of Cardiosurgery and Transplantation
City
Zabrze
State/Province
Silesia
ZIP/Postal Code
41-800
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariusz Gasior, Prof
Phone
004832 273 26 81
First Name & Middle Initial & Last Name & Degree
Marian Zembala, Prof.
First Name & Middle Initial & Last Name & Degree
Mariusz Gasior, Prof
Facility Name
Clinical University Hospital
City
Białystok
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sławomir Dobrzycki, Prog, MD,PhD
Facility Name
Upper Silesian Heart Center of Medical Univeristy of Silesia
City
Katowice
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wojciech Wojakowski, Prof. MD, PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
18237682
Citation
Buszman PE, Kiesz SR, Bochenek A, Peszek-Przybyla E, Szkrobka I, Debinski M, Bialkowska B, Dudek D, Gruszka A, Zurakowski A, Milewski K, Wilczynski M, Rzeszutko L, Buszman P, Szymszal J, Martin JL, Tendera M. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008 Feb 5;51(5):538-45. doi: 10.1016/j.jacc.2007.09.054.
Results Reference
background
PubMed Identifier
19901409
Citation
Buszman PP, Bochenek A, Konkolewska M, Trela B, Kiesz RS, Wilczynski M, Cisowski M, Krejca M, Banasiewicz-Szkrobka I, Krol M, Kondys M, Wiernek S, Orlik B, Martin JL, Tendera M, Buszman PE. Early and long-term outcomes after surgical and percutaneous myocardial revascularization in patients with non-ST-elevation acute coronary syndromes and unprotected left main disease. J Invasive Cardiol. 2009 Nov;21(11):564-9.
Results Reference
background
PubMed Identifier
19699048
Citation
Buszman PE, Buszman PP, Kiesz RS, Bochenek A, Trela B, Konkolewska M, Wallace-Bradley D, Wilczynski M, Banasiewicz-Szkrobka I, Peszek-Przybyla E, Krol M, Kondys M, Milewski K, Wiernek S, Debinski M, Zurakowski A, Martin JL, Tendera M. Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry. J Am Coll Cardiol. 2009 Oct 13;54(16):1500-11. doi: 10.1016/j.jacc.2009.07.007. Epub 2009 Aug 21.
Results Reference
background
PubMed Identifier
20451344
Citation
Park DW, Seung KB, Kim YH, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Gwon HC, Jeong MH, Jang YS, Kim HS, Kim PJ, Seong IW, Park HS, Ahn T, Chae IH, Tahk SJ, Chung WS, Park SJ. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol. 2010 Jul 6;56(2):117-24. doi: 10.1016/j.jacc.2010.04.004. Epub 2010 May 6.
Results Reference
background
PubMed Identifier
20946993
Citation
Park DW, Kim YH, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Kim JJ, Choo SJ, Chung CH, Lee JW, Park SW, Park SJ. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol. 2010 Oct 19;56(17):1366-75. doi: 10.1016/j.jacc.2010.03.097.
Results Reference
background

Learn more about this trial

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

We'll reach out to this number within 24 hrs